Industry Needs To Emphasize Drug Benefits In Response To Risk Concerns, Wyeth Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma industry has become over-regulated, Wyeth R&D head Ruffolo says.
You may also be interested in...
Respect For Precedent Bars FDA From Becoming Too Conservative, Gottlieb Says
Deputy commissioner says “institutional protections” and “decision-making based on past principle” ensure review process is not overly influenced by external pressures.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13